Zelboraf (Vemurafenib) - Published Studies

Zelboraf Related Published Studies

Well-designed clinical trials possibly related to Zelboraf (Vemurafenib)

Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab. [2012]

Other research related to Zelboraf (Vemurafenib)

A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAF V600E mutation-positive metastatic melanoma. [2014]

Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. [2014]

Vemurafenib for the treatment of locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma: a NICE single technology appraisal. [2013]

Vemurafenib and ipilimumab: new agents for metastatic melanoma. [2013]

Analysis of dermatologic events in vemurafenib-treated patients with melanoma. [2013]

BRIM-1, -2 and -3 trials: improved survival with vemurafenib in metastatic melanoma patients with a BRAF(V600E) mutation. [2012]

Vemurafenib (PLX4032): an orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma. [2011]

Improved survival with vemurafenib in melanoma with BRAF V600E mutation. [2011]

Other possibly related research studies

Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011". [2012]

A brief history of melanoma: from mummies to mutations. [2012]

New targeted therapies in melanoma. [2013]

Novel targets in the treatment of advanced melanoma: new first-line treatment options. [2013]

Metastatic melanoma to the brain: surgery and radiation is still the standard of care. [2013]

Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials. [2014]

Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapy. [2013]

Improved overall survival in melanoma with combined dabrafenib and trametinib. [2015]

The use of the EVITA algorithm for clinical assessment of novel agents used in prostate cancer, metastatic melanoma, and systemic lupus erythematosus. [2014]